HCM vs. INSM, LEGN, CTLT, ITCI, ROIV, CERE, ASND, IONS, BPMC, and SMMT
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Insmed (INSM), Legend Biotech (LEGN), Catalent (CTLT), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical preparations" industry.
Insmed (NASDAQ:INSM) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
Insmed presently has a consensus price target of $74.50, indicating a potential downside of 0.05%. HUTCHMED has a consensus price target of $29.70, indicating a potential upside of 60.02%. Given Insmed's higher possible upside, analysts plainly believe HUTCHMED is more favorable than Insmed.
Insmed received 215 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.53% of users gave HUTCHMED an outperform vote while only 65.80% of users gave Insmed an outperform vote.
Insmed has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
HUTCHMED has a net margin of 0.00% compared to HUTCHMED's net margin of -236.74%.
8.8% of HUTCHMED shares are owned by institutional investors. 4.6% of Insmed shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Insmed had 2 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Insmed and 5 mentions for HUTCHMED. Insmed's average media sentiment score of 0.89 beat HUTCHMED's score of 0.80 indicating that HUTCHMED is being referred to more favorably in the news media.
HUTCHMED has higher revenue and earnings than Insmed.
Summary
HUTCHMED beats Insmed on 8 of the 15 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
